CDKN2A and cancer: Approximately 9.2% of cancers exhibited homozygous co-deletion of CDKN2A and MTAP, 3.7% of cancers had CDKN2A HD with wildtype or heterozygous MTAP, and 0.1% of cancers had MTAP HD with wildtype or heterozygous CDKN2A (Fig. 1c, e).